References
- Lupo B , TrusolinoL. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochim. Biophys. Acta1846(1), 201–215 (2014).
- Dizdar O , ArslanC, AltundagK. Advances in PARP inhibitors for the treatment of breast cancer. Expert Opin. Pharmacother.16(18), 2751–2758 (2015).
- Miyoshi Y , MuraseK, OhK. Basal-like subtype and BRCA1 dysfunction in breast cancers. Int. J. Clin. Oncol.13(5), 395–400 (2008).
- Fong PC , BossDS, YapTAet al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med.361(2), 123–134 (2009).
- Kaufman B , Shapira-FrommerR, SchmutzlerRKet al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol.33(3), 244–250 (2015).
- Hong S , FunchainP, HaddadA, CroweJ, DalpiazN, AbrahamJ. Complete durable response from carboplatin and olaparib in a heavily pretreated triple-negative metastatic breast cancer with germline BRCA2 and “BRCAness” mutations. J. Oncol. Pract.12(3), 270–272 (2016).
- Gelmon KA , TischkowitzM, MackayHet al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a Phase 2, multicentre, open-label, non-randomised study. Lancet Oncol.12(9), 852–861 (2011).
- Dent RA , LindemanGJ, ClemonsMet al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res.15(5), R88 (2013).
- Ribeiro E , GanzinelliM, AndreisDet al. Triple negative breast cancers have a reduced expression of DNA repair genes. PLoS ONE8(6), e66243 (2013).
- Koukourakis MI , GiatromanolakiA, BottiniAet al. Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to trastuzumab shows role of HIF1 and autophagy. Br. J. Cancer2110(9), 2209–2216 (2014).